$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 16 Nov 2016 | 32499 | In Stock

Introduction

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

- The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 5

    List of Figures 6

    Introduction 7

    Global Markets Direct Report Coverage 7

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) Overview 8

    Therapeutics Development 9

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Stage of Development 9

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Therapy Area 10

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Indication 11

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Products Glance 14

    Late Stage Products 14

    Early Stage Products 15

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Companies 16

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Universities/Institutes 22

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment 24

    Assessment by Monotherapy/Combination Products 24

    Assessment by Mechanism of Action 25

    Assessment by Route of Administration 27

    Assessment by Molecule Type 28

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30

    Addex Therapeutics Ltd 30

    Array BioPharma Inc. 31

    AstraZeneca Plc 32

    Chronos Therapeutics Limited 33

    Daiichi Sankyo Company, Limited 34

    Exelixis, Inc. 35

    Ignyta, Inc. 37

    Loxo Oncology, Inc. 38

    PharmatrophiX, Inc. 39

    SOM Biotech SL 40

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Drug Profiles 41

    AR-523 - Drug Profile 41

    Product Description 41

    Mechanism Of Action 41

    R&D Progress 41

    AZ-64 - Drug Profile 42

    Product Description 42

    Mechanism Of Action 42

    R&D Progress 42

    AZD-7451 - Drug Profile 43

    Product Description 43

    Mechanism Of Action 43

    R&D Progress 43

    BNN-27 - Drug Profile 44

    Product Description 44

    Mechanism Of Action 44

    R&D Progress 44

    cabozantinib s-malate - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    CTDP-003 - Drug Profile 62

    Product Description 62

    Mechanism Of Action 62

    R&D Progress 62

    DS-6051 - Drug Profile 63

    Product Description 63

    Mechanism Of Action 63

    R&D Progress 63

    entrectinib - Drug Profile 64

    Product Description 64

    Mechanism Of Action 64

    R&D Progress 64

    lestaurtinib - Drug Profile 70

    Product Description 70

    Mechanism Of Action 70

    R&D Progress 70

    LM-22A4 - Drug Profile 71

    Product Description 71

    Mechanism Of Action 71

    R&D Progress 71

    LM-22B10 - Drug Profile 73

    Product Description 73

    Mechanism Of Action 73

    R&D Progress 73

    LOXO-101 - Drug Profile 74

    Product Description 74

    Mechanism Of Action 74

    R&D Progress 74

    PLX-7486 - Drug Profile 78

    Product Description 78

    Mechanism Of Action 78

    R&D Progress 78

    Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 79

    Product Description 79

    Mechanism Of Action 79

    R&D Progress 79

    Small Molecules to Agonize TRKB for Alzheimer’s Disease - Drug Profile 80

    Product Description 80

    Mechanism Of Action 80

    R&D Progress 80

    Synthetic Peptide for Neurology - Drug Profile 81

    Product Description 81

    Mechanism Of Action 81

    R&D Progress 81

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Dormant Projects 82

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Discontinued Products 83

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Featured News & Press Releases 84

    Oct 10, 2016: Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016 84

    Oct 07, 2016: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors 85

    Oct 03, 2016: CABOMETYX (cabozantinib) Tablets Approved for Advanced Renal Cell Carcinoma, Available at Biologics 86

    Sep 27, 2016: Ipsen Announces Data Presentations of Cabozantinib (Cabometyx) at the European Society for Medical Oncology (ESMO) 2016 Congress 87

    Sep 20, 2016: Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress 89

    Sep 19, 2016: EORTC and Ignyta Expand Collaborative Agreement for Precision Medicine 89

    Sep 14, 2016: European Commission Approves Ipsens Cabometyx (Cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma In Adults Following Prior Vascular Endothelial Growth Factor (Vegf)-Targeted Therapy 90

    Sep 06, 2016: Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma 91

    Aug 31, 2016: Exelixis presents cabozantinib data at the ESMO 2016 Congress 92

    Aug 31, 2016: Ignyta Announces Approval of an Investigational Device Exemption (IDE) for the Companion Diagnostic Assay to the STARTRK-2 Trial 94

    Jul 22, 2016: Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy 95

    Jul 13, 2016: Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 97

    Jun 15, 2016: Loxo Oncology Accepts Invitation to Present LOXO-101 to the FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee 97

    Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 98

    May 23, 2016: Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 100

    Appendix 101

    Methodology 101

    Coverage 101

    Secondary Research 101

    Primary Research 101

    Expert Panel Validation 101

    Contact Us 101

    Disclaimer 102

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

32499 | GMDHC0674TDB

Number of Pages

102

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2019
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or Trk...
29 Apr 2019 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2018
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or Trk...
17 Jul 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H1 2018
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or Trk...
31 Jan 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2017
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or Trk...
11 Jul 2017 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Brain Derived Neurotrophic Factor (BDNF) Modulators -Pipeline Insights, 2017
DelveInsight’s, “Brain Derived Neurotrophic Factor (BDNF) Modulators-Pipeline Insights, 2017”, repor...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016
Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016SummaryGlobal Marke...
30 Dec 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...